Floatz logo

asp1893

Testicular Cancer

Astellas Pharma Global Development, Inc.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

10 Active assets in the Testicular Cancer cohort.

Asset / SponsorPhaseRating
TESTOSTERONE UNDECYLATE
University Medical Center Groningen
Phase 2/3BB
Etarfolatide
Endocyte
Phase 2B
FLUOROURACILUM
National Cancer Institute (NCI)
Phase 2B
Eloxatin
National Cancer Institute (NCI)
Phase 2B
Flavopiridol
National Cancer Institute (NCI)
Phase 2B

View all 20 →

Same molecule, other indications

asp1893 is also rated in:

endometrial carcinomaDormant
C
Indicative ·
37 / 100
View asset →
ovarian cancerDormant
C
Indicative ·
36 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →